A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression

Trial Profile

A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Postnatal depression
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Amaryllis
  • Sponsors Marinus Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2018 According to a Marinus Pharmaceuticals media release, data from the open label phase are expected in the fourth quarter of 2018
    • 13 Mar 2018 Planned number of patients changed from 50 to 58.
    • 06 Mar 2018 According to a Marinus Pharmaceuticals media release, Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top